Rationale: The multiligand RAGE (receptor for advanced glycation end products) contributes to atherosclerosis in apolipoprotein (Apo)E-null mice. Objective: To delineate the specific mechanisms by which RAGE accelerated atherosclerosis, we performed Affymetrix gene expression arrays on aortas of nondiabetic and diabetic ApoE-null mice expressing RAGE or devoid of RAGE at nine weeks of age, as this reflected a time point at which frank atherosclerotic lesions were not yet present, but that we would be able to identify the genes likely involved in diabetes-and RAGE-dependent atherogenesis. Methods and Results: We report that there is very little overlap of the genes that are differentially expressed both in the onset of diabetes in ApoE-null mice, and in the effect of RAGE deletion in diabetic ApoE-null mice. Pathway-Express analysis revealed that the transforming growth factor-␤ pathway and focal adhesion pathways might be expected to play a significant role in both the mechanism by which diabetes facilitates the formation of atherosclerotic plaques in ApoE-null mice, and the mechanism by which deletion of RAGE ameliorates this effect. Quantitative polymerase chain reaction studies, Western blotting, and confocal microscopy in aortic tissue and in primary cultures of murine aortic smooth muscle cells supported these findings. Res. 2010;106:1040-1051. )
T he multiligand RAGE (receptor for advanced glycation end products) contributes to atherosclerosis in ApoE-null mice in both the nondiabetic and diabetic states. Previous studies using soluble RAGE or homozygous RAGE-null mice showed that blockade or deletion of RAGE resulted in reduction in atherosclerotic lesion area and complexity compared to control animals. [1] [2] [3] [4] [5] [6] In parallel, significant downregulation of inflammatory mediators and matrix metalloproteinases was evident in ApoE-null mice aortas devoid of RAGE compared to those of RAGE-expressing ApoE-null mice.
Although these findings suggested that RAGE modulated inflammatory gene expression in ApoE-null mouse aorta, they did not reveal the broader pathways by which RAGE contributed to atherosclerosis. We performed Affymetrix gene expression arrays on aortas of nondiabetic and diabetic ApoE-null mice expressing RAGE or devoid of RAGE.
Aortas were harvested in the very early stages of atherogenesis, as our goal was not to identify differential genes and products expression in the atherosclerotic lesion, but to identify RAGE-dependent regulatory mechanisms in the aorta before the development of frank plaques.
Quantification of Atherosclerotic Lesion Area
The frozen sections from aortic roots were fixed in 10% buffered formalin. Six 6-m sections were collected at 80-m intervals starting at a 100-m distance from the appearance of the aortic valves. The sections were stained with oil red O and counterstained with hematoxylin. Atherosclerotic lesion areas were quantified using a Zeiss microscope and image analysis system (AxioVision 4.5). Four serial sections each were placed on 6 slides (total 24 sections), and mean lesion areas were calculated by determining the mean lesion area of one section/slide for a total of 6 sections examined. The investigator was blinded to the experimental conditions. The statistical significance of changes in atherosclerotic lesion area between diabetic ApoE-null and ApoE /RAGE-null mice was determined using the 2 sample t test.
RNA Isolation and GeneChip Analysis
High-quality RNA samples were extracted from 4 groups mice at age 9 weeks: diabetic ApoE-null (nϭ4), nondiabetic ApoE-null (nϭ4), diabetic ApoE-null/RAGE-null (nϭ4), and nondiabetic ApoE-null/ RAGE-null aortas (nϭ3). We used RNA from 3 mice in the last group secondary to failure to generate cRNA from one of the mice. Total aortic RNA was isolated by using TRIzol (Invitrogen, Carlsbad, Calif) and RNeasy MinElute Cleanup (QIAGEN Inc, Valencia, Calif) including a DNase step. Total RNA concentration and quality were assessed on a 2100 Bioanalyzer system (Agilent Technologies, Parsippany, NJ). All of the samples displayed an RNA integrity score Ͼ8, and there was no indication of RNA degradation or contamination with DNA. To prepare for expression analyses, cDNA was in vitro transcribed into biotin-labeled antisense cRNA using an Affymetrix kit according to the standard kit protocol. RNA (1 g) from each sample was hybridized to Affymetrix Mouse Genome 430 2.0 GeneChips (Gene Expression Omnibus Platform Accession number Gene symbols that are colored reflect genes that are statistically significantly differentially expressed in ApoE-null mice with diabetes relative to nondiabetic ApoE-null mice. Upregulated genes are shown in red, and downregulated genes are shown in blue. Numbers indicate perturbation factors (which may be different in magnitude and even in sign than fold-changes). KEGG pathways often represent several different and related proteins by a single protein (for example, Tgf-␤1, Tgf-␤2, and Tgf-␤3 are all represented as Tgf-␤). In such a case, the perturbation factor for the product of the gene with nonzero fold change is given. 
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Real-Time RT-PCR Validation
The differential expression of especially interesting genes was validated using RT-PCR. Total aortic RNA (0.5 g) was reverse-transcribed with SuperScript II (Invitrogen). After dilution of the cDNA to 50 L, 1.5 L of cDNA was amplified by real-time PCR on a sequence detection system (Prism 7900HTl; ABI, Foster City, Calif). ABI Assay-on-Demand kits containing primers and probes for mouse transforming growth factor-␤2 (mTgfb2) (Mm01321738_m1), mouse thrombospondin-1 (mThbs1) (Mm01335418_m1), and mouse rhoassociated protein kinase (mROCK)1 (Mm01225244_g1) were used. 18S rRNA was used as an endogenous reference to correct for differences in the amount of RNA.
Western Blot Analysis
Total lysate from mouse aorta was immunoblotted and probed with antibodies to Thbs1, Tgf-␤2, and ROCK1.
Immunohistochemistry
Acetone-fixed cryostat aortic sections were subjected to confocal microscopy for detection and merged images of RAGE, Thbs1, Tgf-␤2, and ROCK1 in endothelium and smooth muscle layers using specific antibodies and Bio-Rad Radiance 2000 Confocal System and the Lasersharp 2000 software (Bio-Rad).
ROCK1 Activity Assays and Primary Smooth Muscle Cell Studies
Smooth muscle cells (SMCs) were retrieved from the aortas of wild-type and RAGE-deficient mice and subjected to ROCK1 activity assays 7-8 and assessment of proliferation and migration as described in the Online Data Supplement (expanded Methods section).
Results
We previously established that deletion of RAGE in nondiabetic ApoE-null mice reduced atherosclerosis at age 14 weeks. 5 To test these concepts in diabetes, we performed studies in RAGE-expressing or ApoE-null/RAGE-null mice rendered diabetic at age 6 weeks. At 14 weeks of age, mean atherosclerotic lesion area at the aortic root in diabetic ApoE-null mice was Ϸ2.8-fold higher in RAGE-expressing versus RAGE-deficient ApoE-null animals (1.59Ϯ0.23 vs 0.57Ϯ0.03ϫ10 5 m 2 , respectively; PϽ0.003) (Online Figure  I, A) . Other studies showed that diabetes accelerates atherosclerosis in ApoE-null mice after 6, 14, or 20 weeks of hyperglycemia. 1, 3, 6 We examined factors that might account for the beneficial effects of RAGE deletion. Diabetic mice displayed a significantly higher plasma glucose level than nondiabetic mice, and, importantly, there was no statistically significant dependence of the glucose concentration of either diabetic or nondiabetic mice on RAGE expression (Online Table I ). The plasma cholesterol concentration and body weights of the mice are given in Online Tables II and III and reveal no statistically significant dependence of cholesterol concentration or body weight on either genotype or disease state. Furthermore, we characterized the cellular lesion content by determining the percentage of macrophages per lesion area, the percentage of SMCs per lesion area, and the percentage of T cells per lesion area. At age 24 weeks (18 weeks of hyperglycemia), an age at which significant lesions formed in RAGE-expressing ApoE-null mice (see Online Figure I Figure I, B ). Furthermore, nondiabetic ApoE-null/ RAGE-null mice displayed approximately 7% collagen per lesion area, whereas in nondiabetic ApoE-null mice lesions, scant collagen was detected (Online Figure I, B ). In the diabetic state, a nearly 2-fold higher percentage of collagen content in ApoE-null/RAGE-null mice lesions versus ApoEnull mice was observed (Online Figure I, B ).
Therefore, our data indicate that RAGE contributed importantly to atherosclerosis in ApoE-null mice in a manner independent of glucose, cholesterol, or body weight. We sought to identify the specific mechanisms by which RAGE contributed to early atherogenesis in ApoE-null mice and retrieved entire aortas from nondiabetic and diabetic ApoEnull mice at age 9 weeks, a time point at which the mice had not yet developed gross atherosclerotic plaques. Hence, our analyses would not detect genes prevalent in atherosclerotic lesions, but in genes over-or underrepresented in early atherogenesis in the aorta as dependent on the state of The number of unique genes with the Bayesian log odds factor B Ͼ0 (indicating that the odds of differential expression is greater than 1) are reported. Only genes with GenBank symbols were counted, and genes with more than one probe set were only counted once. Using these parameters, we report that the onset of diabetes affects transcription in ApoE-null mice (53 genes, comparison 1) more than in ApoE-null/RAGE-null mice (3 genes, comparison 3), and that deletion of the RAGE gene in ApoE-null mice affects transcription much more if the mice are diabetic (216 genes, comparison 4) than if they are nondiabetic (0 genes, comparison 2). Finally, more genes are affected by deletion of RAGE in diabetic ApoE-null mice (216 genes, comparison 4) than by onset of diabetes in ApoE-null mice (53 genes, comparison 1). Online Tables IV and V show the log fold changes (log 2 FC) and B values for all genes with BϾ0 for comparison 1 and comparison 4, respectively, the 2 comparisons with a nonnegligible number of differentially expressed genes.
We performed a Pathway-Express analysis on the gene lists in Online Tables IV and V to determine the pathways that were most associated with the onset of diabetes in ApoE-null mice and the effect of RAGE gene deletion in diabetic ApoE-null mice. Statistically significant pathways (with a ␥ probability value corrected for false discoveries of Յ0.05) are listed in Online Tables VI and VII. Tgf-␤2 and focal adhesion pathways are common to both lists, suggesting that these pathways play a significant role in both the mechanism by which diabetes facilitates the formation of atherosclerotic plaques in ApoE-null mice, and the mechanism by which deletion of RAGE ameliorates this effect. Thus, we focused on the Tgf-␤ pathway, because of the established role for this pathway in atherogenesis. 9 -15 The Tgf-␤ pathway, with the genes that are differentially expressed indicated for the 2 comparisons under consideration are given in Figures 1 and 2 . The genes that are differentially expressed in each comparison are given in Online Tables VIII and IX. The genes whose perturbation factors 16 are changed in each comparison are given in Online Tables X and XI. Genes without a statistically significant change may still have nonzero perturbation factor. Perturbation factors are defined briefly in the Online Data Supplement (expanded Methods section).
Online Table VIII shows that expression of Thbs1 mRNA is increased in diabetic ApoE-null mice compared to nondiabetic ApoE-null mice (comparison 1). Online Table IX shows that expression of Thbs1 mRNA is lower in diabetic ApoE-null/RAGE-null mice relative to diabetic ApoE-null mice (comparison 4). Analysis of Figures 1 and 2 reveals that latent Tgf-␤ binding protein (Ltbp)1 is an inhibitor of Tgf-␤2. [17] [18] [19] Because Thbs1 inhibits the suppressive effect of Ltbp1 on activation of Tgf-␤2, our results suggest that in diabetic ApoE-null mice, the effect of increased Thbs1 mRNA expression is to activate Tgf-␤2 protein. Similarly, Figure 2 suggests that the reduction of Thbs1 expression in diabetic ApoE-null/RAGE-null mice relative to nondiabetic ApoE-null mice deactivates Tgf-␤2 protein. Figure 2 and Online Table IX list other genes in the Tgf-␤ pathway whose expression is reduced in comparison 4. Furthermore, in addition to Thbs1 and Tgf-␤2, ROCK1 is also linked to atherogenesis. 20 -22 We validated the microarray results for Thbs1, Tgf-␤2, and ROCK1 by real-time quantitative PCR, followed by Western blotting (Table and Figure 3 ). These data reveal that diabetes increases protein levels of Thbs1, Tgf-␤2, and ROCK1 in ApoE-null aorta, and that particularly in the diabetic state; deletion of RAGE suppresses diabetes-linked upregulation of Thbs1, Tgf-␤2, and ROCK1 protein in ApoE-null aorta.
To identify the specific histological distribution of the key molecules identified in this model, we immunostained mouse aorta sections from the 4 groups of mice and subjected these sections to confocal microscopy (Figure 4 ). First, we examined the expression of RAGE in the aorta of ApoE-null mice at age 9 weeks ( Figure 4 ). RAGE is absent in the RAGE-null animals, as has been observed previously. 5 In both nondiabetic and diabetic ApoE-null mice, RAGE (green) is expressed in SMCs (␣-smooth muscle actin (red) ( Figure 4A ), as indicated by the (yellow) merged images in column 3. Furthermore, RAGE (green) and CD31/PECAM1 (platelet/ endothelial cell adhesion molecule 1) (red) are colocalized, indicating that RAGE is also expressed in the endothelial cell (EC) ( Figure 4B ).
We next focused on the cellular localization of the 3 key genes of the Tgf-␤ pathway identified in these studies. Figure  4C shows colocalization of Thbs1 with RAGE. The Thbs1 and ␣-smooth muscle actin images merge under all 4 conditions, indicating colocalization of the 2 proteins in the smooth muscle layer ( Figure 4D) , consistent with what has been observed previously. 23 However, the Thbs1 and CD31/PE-CAM1 images do not merge under any of the 4 conditions ( Figure 4E ), indicating that Thbs1 is not expressed to appreciable degrees in the endothelial layer of ApoE-null mice at age 9 weeks, although Thbs1 expression in ECs has been noted in other settings. 24 Tgf-␤2 is coexpressed with RAGE in the aorta ( Figure 4F ). In all cases, Tgf-␤2 merges with RAGE and ␣-smooth muscle actin or CD31/PECAM1, with the exception of CD31/ PECAM1 in nondiabetic ApoE-null mice, indicating that Tgf-␤2 is expressed in SMCs in all conditions and in endothelial layers in diabetic but not nondiabetic ApoE-null mice aorta ( Figure 4G and 4H ). Furthermore, ROCK1 is colocalized with RAGE ( Figure 4I ). Furthermore, ROCK1 and ␣-smooth muscle actin are also colocalized, indicating that ROCK1 is expressed in the smooth muscle layer ( Figure  4J ). The images of ROCK1 and CD31/PECAM colocalize only weakly in nondiabetic and diabetic ApoE-null mice ( Figure 4K) . These findings suggest that ROCK1 is predominantly expressed in the smooth muscle layer in early atherogenesis in ApoE-null aorta, but previous studies have noted EC expression as well. 25 As our analyses suggested that the ROCK1 branch of the Tgf-␤ pathway is importantly involved in RAGE-dependent atherogenesis, we sought to assess the activation state of ROCK1 in aorta and measured the relative quantity of phosphorylated MYPT1/Ppp1r12a (myosin phosphatase target subunit 1/protein phosphatase 1, regulatory [inhibitor] subunit 12A), which is directly phosphorylated by ROCK1. Figure 5A shows the extent of MYPT1/Ppp1r12a phosphorylation increase in diabetic ApoE-null mouse aorta relative to nondiabetic ApoE-null mice aorta, and diabetic ApoE-null/ RAGE-null mice reveal significantly less MYPT1/Ppp1r12a phosphorylation versus diabetic ApoE-null mice.
Furthermore, as SMCs were the primary cell type expressing ROCK1 in the aorta, we isolated SMCs from the aortas of wild-type and RAGE-null mice and treated them with RAGE ligand S100B. Although primary aortic SMCs from wild-type mice displayed increased ROCK1 activity on incubation with RAGE ligand, S100B, SMCs from RAGE-null mice failed to increase ROCK1 activity under these conditions ( Figure 5B ).
Our data reveal that the observed changes in the Tgf-␤ pathway are typical of changes in transcription associated with atherogenesis accompanying the onset of diabetes in ApoE-null mice and the effect of RAGE deletion in diabetic ApoE-null mice. Online Table XII provides the numbers of differentially expressed unique genes (as distinct from probe sets) for each comparison that have Entrez Gene symbols and the numbers with positive and negative log fold changes. In addition, this table gives the numbers of genes resulting from Boolean operations on these gene lists. Online Tables XIII through XVII give the lists of genes whose numbers are given in Online Table XII . Online Figure II Next, to specifically link RAGE to SMC proliferation and migration, we performed studies in primary SMCs retrieved from RAGE-expressing or RAGE-deficient mouse aortas. As illustrated in figure 6A and 6B, incubation of wild-type SMCs with RAGE ligand S100B resulted in significantly increased proliferation and migration, but S100B failed to stimulate proliferation and migration in RAGE-deficient SMCs. Note that in wild-type and RAGE-deficient SMCs, incubation with Tgf-␤2 or a non-RAGE ligand platelet-derived growth factor increased proliferation and migration, suggesting that Tgf-␤2 and platelet-derived growth factor are not direct ligands of RAGE, that RAGE deficient SMCs are capable of proliferation and migration, and that exogenous addition of Tgf-␤2 to RAGE-deficient cells restores proliferation and migration ( Figure 6A and 6B, respectively) .
Finally, to establish that RAGE ligand-stimulated SMC proliferation and migration required Tgf-␤2 and ROCK1 action, we treated wild-type SMCs with S100B in the presence or absence of Tgf-␤2 or ROCK1 inhibitors. Consistent with key roles for Tgf-␤2 in S100B-mediated effects on SMCs, pretreatment of wild-type SMCs with anti-Tgf-␤2 antibody resulted in a significant decrease in proliferation and migration compared to treatment with IgG control ( Figure 6C and 6D, respectively) . ROCK signaling was implicated in the S100B modulation of SMC properties, as treatment of SMCs with S100B and ROCK inhibitors Y27632 or fasudil significantly reduced S100B- Aortas were retrieved from the indicated mice at age 9 weeks (A) or primary murine aortic SMCs were treated with S100B (10 g/mL) for the indicated times (B). Lysates were prepared, and ROCK1 activity was determined. Statistical considerations from at least nϭ3 distinct experiments are indicated. stimulated proliferation and migration ( Figure 6E and 6F, respectively). Note that treatment with anti-Tgf-␤2 antibody, Y27632, or fasudil alone had no independent effect on SMC migration or proliferation ( Figure 6C through 6F ).
Discussion
In summary, these findings lead us to speculate on the mechanisms by which diabetes accelerates atherogenesis in ApoE-null mice (comparison 1) and by which RAGE deletion slows atherogenesis in diabetic ApoE-null mice (comparison 4), as illustrated in Figure 7 . (A formal set of rules for the derivation of the model in Figure 7 is given in the Online Data Supplement [expanded Methods section].) First, we consider the effect of diabetes on ApoE-null mice (comparison 1) ( Figure 7A ). All changes in quantity of mRNA and total and activated protein in this column reflect that in diabetic ApoE-null mice versus nondiabetic ApoE-null mice. We infer the mechanism based on Figures 1 and 2 and Online Tables X and XI as follows: (A1) diabetes upregulates Thbs1; (A2) no change in levels of LTBP1 was detected for this comparison; (A3) the amount of activated Tgf-␤2 may increase because the total amount of Tgf-␤2 increases, and because of increased activation attributable to upregulation of Thbs1; (A4) because Tgf-␤2 activates Tgf-␤R1/2 complex (TGFBR) and because the amount of activated Tgf-␤2 increases, the amount of activated TGFBR increases; (A5 and A6) because no change in the amount of SMURF2 mRNA was detected in this comparison, interaction with SMURF2, which targets A and B , Wild-type and RAGE-deficient SMCs were treated with S100B (10 g/mL), Tgf-␤ (10 ng/mL), or platelet-derived growth factor (PDGF) (10 ng/mL) for 5 or 48 hours, and at the end of that time, proliferation (A) and migration (B) were assessed. Note that when comparing migration and proliferation responses to S100B between wild-type and RAGE-null SMCs: PϽ0.05. C and D, Wild-type SMCs were pretreated anti-Tgf-␤ antibody or irrelevant IgG control antibody (10 g/mL), followed by assessment of S100B-stimulated proliferation and migration. E and F, Wild-type SMCs were pretreated with Y27632 (10 mol/L) or fasudil (10 mol/L) followed by S100B (10 g/mL), and proliferation and migration were monitored. Statistical considerations from at least nϭ3 distinct assays are shown.
Tgf-␤1 for destruction, 26 will not change the amount of total or activated Tgf␤-R; (A7) because Tgf-␤R complex indirectly activates RhoA, 27, 28 and because the amount of activated Tgf-␤R complex increases, the amount of activated RhoA increases; (A8) because RhoA activates ROCK1, 29, 30 and because the amount of activated RhoA increases, the amount of activated ROCK1 increases; (A9) because ROCK1 accelerates atherogenesis, and because the extent of ROCK1 activation increases, acceleration of atherosclerosis ensues. It should be noted that although Tgf-␤ from immune cells has been reported to reduce atherosclerosis, 9 -15 Tgf-␤ action in SMCs has been linked to their proliferation, hypertrophy, migration, and production of extracellular matrix. [31] [32] [33] Next, we address the mechanism by which RAGE deletion delays acceleration of atherosclerosis in diabetic ApoE-null mice ( Figure 7B ). All changes in quantity of mRNA and total and activated protein in this column are for diabetic ApoEnull/RAGE-null versus diabetic ApoE-null mice (comparison 4) unless otherwise specified. (B1) The amount of Thbs1 decreases on deletion of RAGE; (B2) LTBP1 expression decreases; (B3) the amount of activated Tgf-␤2 decreases as the total amount of Tgf-␤2 decreases (the proportion of activated Tgf-␤2 decreases because of the decrease in Thbs1; however, this effect may be cancelled, all or in part, by the decrease in Tgf-␤2 deactivation by LTBP1 accompanying the decrease in LTBP1); (B4) because Tgf-␤2 activates Tgf-␤R, and because the amount of activated Tgf-␤2 decreases, the amount of activated complex decreases; (B5) the amount of SMURF2 decreases; (B6) because SMURF2 deactivates Tgf-␤R1, and the amount of SMURF2 decreases, the amount of Tgf-␤R1 increases, canceling all or part of the effect of decrease in activated Tgf-␤R in step B4; (B7) because Tgf-␤R complex indirectly activates RhoA, and because the amount of activated Tgf-␤R is approximately unchanged, the amount of activated ROCK1 is also approximately unchanged; (B8) the total amount of ROCK1 decreases (be- Figure 7 . Proposed mechanism by which diabetes and RAGE contribute to atherosclerosis in ApoE-null mice. Based on in-depth analysis of microarray findings, we speculate on the mechanisms by which diabetes accelerates atherosclerosis in ApoE-null mice (A) and by which RAGE accelerates atherosclerosis in diabetic ApoE-null mice (B). In both cases, the left column represents the pathway, and the right column represents the observed change in concentration of mRNA and protein and inferred change in activation of proteins and processes. Numbers accompanying each molecular step are Pathway Express perturbation factors. Note that Tgf-␤R appears in 2 steps for the sake of reliability, but only has 1 perturbation factor, as any other protein in the pathway. ATHERG indicates atherogenesis.
cause the amount of activated RhoA remains roughly constant, and the total amount of ROCK1 decreases, the amount of activated ROCK1 decreases); (B9) because ROCK1 accelerates atherosclerosis, 18 -20 and because the amount of activated ROCK1 decreases, atherosclerosis is reduced.
Studies have implicated the ROCK1 signaling pathway in human vascular cells and atherosclerosis. 34 -36 Our results in vivo revealed that RAGE-deficient ApoE-null mice displayed reduced ROCK1 activity in the aorta and in vitro, stimulation of wild-type SMCs with RAGE ligand S100B mediates proliferation and migration of these cells in a manner suppressed by 2 distinct inhibitors of ROCK. Of note, a previous study in cultured ECs suggested that antibodies to RAGE blocked AGE-stimulated endothelial hyperpermeability presumably through effects on ROCK and phosphorylation of moesin. 37 It is important to note that roles for RAGE in atherosclerosis have been shown in an additional mouse model, that is, mice deficient in low-density lipoprotein receptor. When these mice were bred into the RAGE-null background and fed high-fat diet, reduction of atherosclerosis was observed compared to RAGE-expressing controls. 38 The potential effect of RAGE signaling on Tgf-␤/ROCK in this model remains to be addressed.
Taken together, these data reveal that suppression of Tgf-␤/ROCK1 activity in the atherosclerosis-vulnerable vessel wall, especially in diabetes, but in nondiabetic conditions as well, may underlie the beneficial effects of RAGE antagonism and genetic deletion in ApoE-null mice.
